The Pharma Data

DECEMBER 17, 2020

In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but lack the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation, the company said. “At Janux, in exchange, will receive up to $500.5

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

Drug Target Review

OCTOBER 2, 2024

While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. As with all CGTs, safety concerns, particularly related to immune responses and long-term effects, are crucial in cardiology. Allogeneic cell therapies must avoid immune rejection.

Therapies 98

Therapies Disease Engineering RNA 98

Broad Institute

JUNE 14, 2023

A trailblazer in cancer research, Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. She has also received the 2017 George M.

Medical Schools 52

Medical Schools Immune Response Science Hospitals 52

PerkinElmer

AUGUST 25, 2019

1 AlphaLISA ® Assay Technology Studies done using human tumor cell lines by PerkinElmer Application Scientist Jeanine Hinterneder have contributed to our understanding of how tumor cells develop the ability to evade the immune response. When that occurs the cancer becomes more severe.

Protein Expression 52

Protein Expression Immune Response Treatment Research 52

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. About CEPI.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CHENGDU, China , Feb. About CEPI.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Drug Target Review

FEBRUARY 28, 2024

Prior to the founding of IN8bio, from 2014 to 2017, Mr Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. gammadelta T cells link innate and adaptive immune responses. Mr Ho has worked in the biotechnology industry for almost 20 years. References Fichtner A, Ravens S, Prinz I.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Target Review

MARCH 21, 2024

AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. About the author Aki Ko, Chief Executive Officer & Co-Founder, Board Chairman, Elixirgen Therapeutics Aki Ko has served as Chief Executive Officer and Chair of the Board of Directors since May 2017, when he co-founded the company.

Therapies 64

Therapies RNA Immune Response Treatment 64

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour. in North America) in late 2017.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

Drug Target Review

DECEMBER 5, 2024

1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2. 2 Since then, the FDA has approved four more AAV-based gene therapies—Zolgensma, Hemgenix, Elevidys and Rocktavian—for treating various diseases.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

SEPTEMBER 10, 2021

Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Since the first approval in May 2017, more than 100,000 patients have been treated with Imfinzi.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

NOVEMBER 10, 2020

Oral administration of anti-CD3 monoclonal antibody is a novel approach to induce an anti-inflammatory immune response to suppress inflammation by inducing T regulatory (Tregs) cells in animal studies 3 ,4. 2012) Induction of immunological tolerance by oral anti-CD3. Clin Dev Immunol 2012, 425021. Preston-Hurlburt, P., Shailubhai, K.,

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

DECEMBER 15, 2020

In November, Cue Biopharma extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an undisclosed autoimmune disease.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JANUARY 3, 2021

Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. 2017; 61(3): e01714-16. The primary analysis was based on 5,172 participants who did not have SARS-CoV-2 infection at baseline. Antimicrob Agents Chemother. Yu XQ, et al.

Trials 52

Trials Virus Vaccine Pharmacokinetics 52

The Pharma Data

JUNE 18, 2021

The FDA previously granted Fast Track designation for PREVNAR 20 in September 2017 for use in adults aged 18 years or older. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved based on immune responses. Adults with weakened immune systems (eg, HIV infection, leukemia) may have a reduced immune response.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Trials 40

Trials DNA Treatment Therapies 40

The Pharma Data

NOVEMBER 1, 2020

Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

OCTOBER 22, 2020

The lowest number of WPV1 cases was reported in 2017, when only 22 cases were found. Routine immunization particularly outreach services was the area most frequently reported as disrupted. . No wild polio cases have been detected outside of Pakistan and Afghanistan since the last cases in Nigeria in 2016 four years ago.

Vaccine 52

Vaccine International Immune Response Virus 52

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. 20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein].

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

MARCH 16, 2021

TREMFYA is the first and only treatment approved for both adults with moderate to severe plaque PsO and for adults with active PsA that selectively inhibits IL-23, a cytokine that is a key driver of the inflammatory immune response associated with the symptoms of these chronic autoimmune diseases. TREMFYA was approved in the U.S.

Treatment 52

Treatment Disease Pharmacokinetics Therapies 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2017; 377 (10): 936-946. 2019 May 23;380(21):2082].

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

OCTOBER 28, 2020

Adults with COVID-19 ARDS As cases of COVID-19 surge in the United States and globally, deaths continue to increase from ARDS in ventilator-dependent patients as a result of an overactive immune response in the lungs to COVID-19. AHA’s 2017 Heart Disease and Stroke Statistics 7.Decision CDC Facts and Figures 2015.

Treatment 40

Treatment Trials Disease Production 40

The Pharma Data

DECEMBER 21, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2017; 377 (10): 936-946. 3,12. .

Trials 40

Trials Production Clinical Trials Therapies 40

The Pharma Data

JULY 23, 2021

Opdivo was first granted this indication in 2017 under the FDA’s accelerated approval program, making it the first immunotherapy agent to be approved for use in this setting. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. About Opdivo.

Treatment 52

Treatment Trials Therapies Disease 52

The Pharma Data

MARCH 11, 2021

In 2017, Opdivo was granted accelerated approval by the FDA as a single agent for patients with HCC who have been previously treated with sorafenib. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. About Opdivo.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

In addition, the observed median PFS shows that the regimen can induce a sustained and durable response, which is also shown consistently by the induction of a specific immune response. Cancer Immunol Res 2017; 5: 417 -424. [10]. Tumeh et al. .

Vaccine 40

Vaccine Trials Treatment Virus 40

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. Immune responses in checkpoint myocarditis across heart, blood and tumour. Goodman Fellowship. Paper Cited Blum S, Zlotoff D, et al.

Immune Response 125

Immune Response Medical Schools Clinical Trials Treatment 125

Broad Institute

NOVEMBER 6, 2024

Motivated to make immunotherapy safer, Reynolds teamed up with researcher Alexandra-Chloé Villani to launch the Severe Immunotherapy Complications (SIC) Service and Clinical-Translational Research Effort in 2017. Patients can even develop life-threatening organ inflammation after a single dose. How did you go about launching this effort?

Research 131

Research Immune Response Hospitals Therapies 131

Drug Target Review

NOVEMBER 7, 2024

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52

Disease Immune Response Regulations Engineering 52

Drug Target Review

FEBRUARY 25, 2025

These immune cells are critical to the bodys ability to mount an effective anti-tumour response. However, the use of IL-15 in cancer therapy has been limited by its short half-life and limited ability to engage the full spectrum of immune responses. This is where NKTR-255 comes into play.

Therapies 52

Therapies Immune Response Treatment Clinical Trials 52

PLOS: DNA Science

JULY 25, 2024

A virus that directly attacks the immune response presents a special challenge. By 2017, a mosquito eradication campaign that decreased cases by 95% ended the Zika public health emergency in Brazil. Dr. Fauci had read about it in med school, but had never encountered a case.

Virus 97

Virus Science Vaccine Government 97